Publications by authors named "Lynn R Kong"
Standard single-agent nonplatinum chemotherapy provides only modest benefit in a small proportion of patients with platinum-resistant/-refractory ovarian cancer, with objective response rates of 6-20% and progression-free survival of ≈3-4 months. Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel cytokine designed to capture and expand the therapeutic potential of high-dose interleukin-2 (IL-2) while mitigating its associated toxicity issues. Nemvaleukin preferentially activates cytotoxic CD8 T cells and natural killer cells with minimal, non-dose-dependent effects on CD4 regulatory T cells.
View Article and Find Full Text PDFBACKGROUND Patients with advanced stage ovarian cancer typically have vague non-specific abdominal symptoms related to pelvic tumor, metastasis, and ascites. When these patients present with more acute abdominal pain, appendicitis is rarely considered. Acute appendicitis due to metastatic ovarian cancer has been sparsely documented in the medical literature; only twice, to our knowledge.
View Article and Find Full Text PDFArticle Synopsis
- The document aims to guide the use of opioids for managing pain in adults suffering from cancer or its treatment.
- A systematic review analyzed 31 systematic reviews and 16 randomized controlled trials, which showed that opioids effectively reduce moderate-to-severe cancer pain but have well-known side effects.
- Recommendations include prescribing opioids for cancer-related pain as needed and at the lowest effective dose, while monitoring for adverse effects and collaborating with specialists for patients with a substance use disorder.